578 related articles for article (PubMed ID: 33385521)
1. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M; Zielinski C; Ruiz-Borrego M; Carrasco E; Turner N; Ciruelos EM; Muñoz M; Bermejo B; Margeli M; Anton A; Kahan Z; Csöszi T; Casas MI; Murillo L; Morales S; Alba E; Gal-Yam E; Guerrero-Zotano A; Calvo L; de la Haba-Rodriguez J; Ramos M; Alvarez I; Garcia-Palomo A; Huang Bartlett C; Koehler M; Caballero R; Corsaro M; Huang X; Garcia-Sáenz JA; Chacón JI; Swift C; Thallinger C; Gil-Gil M
Ann Oncol; 2021 Apr; 32(4):488-499. PubMed ID: 33385521
[TBL] [Abstract][Full Text] [Related]
2. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Martín M; Zielinski C; Ruiz-Borrego M; Carrasco E; Ciruelos EM; Muñoz M; Bermejo B; Margelí M; Csöszi T; Antón A; Turner N; Casas MI; Morales S; Alba E; Calvo L; de la Haba-Rodríguez J; Ramos M; Murillo L; Santaballa A; Alonso-Romero JL; Sánchez-Rovira P; Corsaro M; Huang X; Thallinger C; Kahan Z; Gil-Gil M
Eur J Cancer; 2022 Jun; 168():12-24. PubMed ID: 35429901
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
5. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F; Marce M; Delaloge S; Hardy-Bessard AC; Bachelot T; Bièche I; Pradines A; De La Motte Rouge T; Canon JL; André F; Arnould L; Clatot F; Lemonnier J; Marques S; Bidard FC;
BMJ Open; 2022 Mar; 12(3):e055821. PubMed ID: 35241469
[TBL] [Abstract][Full Text] [Related]
6. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
[TBL] [Abstract][Full Text] [Related]
7. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC; Hardy-Bessard AC; Dalenc F; Bachelot T; Pierga JY; de la Motte Rouge T; Sabatier R; Dubot C; Frenel JS; Ferrero JM; Ladoire S; Levy C; Mouret-Reynier MA; Lortholary A; Grenier J; Chakiba C; Stefani L; Plaza JE; Clatot F; Teixeira L; D'Hondt V; Vegas H; Derbel O; Garnier-Tixidre C; Canon JL; Pistilli B; André F; Arnould L; Pradines A; Bièche I; Callens C; Lemonnier J; Berger F; Delaloge S;
Lancet Oncol; 2022 Nov; 23(11):1367-1377. PubMed ID: 36183733
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
10. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
12. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
[TBL] [Abstract][Full Text] [Related]
13. Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Lee S; Park K; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park WY; Im SA; Park YH
Breast; 2022 Apr; 62():52-60. PubMed ID: 35124320
[TBL] [Abstract][Full Text] [Related]
14. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
15. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
[TBL] [Abstract][Full Text] [Related]
16. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2- patients with metastatic breast cancer.
Li J; Zhang X; Yang C; Lv Y; Yang H; Kong X; Han M; Wang Z; Ma J; Han J; Liu Y
Medicine (Baltimore); 2021 Nov; 100(44):e27710. PubMed ID: 34871262
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
